Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Corrector combination therapies for F508del-CFTR.

Current opinion in pharmacology - 1 Jun 2017

Hanrahan John W, Matthes Elizabeth, Carlile Graeme, Thomas David Y

Abstract excerpt

These are exciting times in the development of therapeutics for cystic fibrosis (CF). New correctors and potentiators of the cystic fibrosis transmembrane conductance regulator (CFTR) are being developed in academic laboratories and pharmaceutical companies, and the field is just beginning to understand their mechanisms of action. Studies of CFTR modulators are also yielding insight into the general principles...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Binding Sites
Share to Chloride Channel Agonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Drug Therapy, Combination

Share to Mutation

Share to Quinolones

Source

Identifiers

PMID: 29080476
DOI: 10.1016/j.coph.2017.09.016

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Corrector combination therapies for F508del-CFTR.PMID 29080476Read ↗

Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.Semantic proximity Read ↗

Cystic fibrosis transmembrane regulator correctors and potentiators.Semantic proximity Read ↗

Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors.Semantic proximity Read ↗

Toward inclusive therapy with CFTR modulators: Progress and challengesSemantic proximity Read ↗

Discovery of GLPG2737, a Potent Type 2 Corrector of CFTR for the Treatment of Cystic Fibrosis in Combination with a Potentiator and a Type 1 Co-corrector.Semantic proximity Read ↗

A systematic cochrane review of corrector therapies (with or without potentiators) for people with cystic fibrosis with class II gene variants (most commonly F508DEL).Semantic proximity Read ↗

Structure-guided combination of novel CFTR correctors to improve the function of F508del-CFTR in airway epithelial cells.Semantic proximity Read ↗

New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.Semantic proximity Read ↗

Towards next generation therapies for cystic fibrosis: Folding, function and pharmacology of CFTR.Semantic proximity Read ↗

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).Semantic proximity Read ↗

Current development of CFTR potentiators in the last decade.Semantic proximity Read ↗

Functional Rescue of F508del-CFTR Using Small Molecule CorrectorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.